IRCT20200105046010N113招募中Unknown
In-vivo Bioequivalence Study of Palbociclib 125 mg Hard Capsules of The Test Drug (IBRACT®, 125 mg Cap., Actero Pharma, Iran) in Compared with The Reference Drug (IBRANCE® 125 mg Cap., Pfizer Inc. Ireland) In Iranian Healthy Volunteers
Actro Middle East Pharmaceutical Co0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-30)
- •Informed consent
- •Age (18-60years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Palbociclib
研究者
相似试验
招募中
Unknown
In-vivo Bioequivalence Study of Palbociclib 125 mg Hard Capsules of The Test Drug (PADENZA®, Abidi Pharma, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N112Abidi Pharmaceutical Company24
招募中
Unknown
In-vivo Bioequivalence Study of Palbociclib 125 mg Hard Capsules of The Test Drug (PALBRANCE®, Arena Hayat Danesh, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N116Arena life science24
招募中
Unknown
In vivo Bioequivalence study of Palbociclib capsuleIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N19Tabriz University of Medical Sciences24
进行中（未招募）
1 期
A study for patients with metastatic breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-003170-27-IEGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)550
进行中（未招募）
1 期
A study for patients with advanced breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.EUCTR2013-003170-27-LVGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)601